Could cause temporary or reversible harm; serious harm is unlikely.
CGMP Deviations: Various strengths of ibuprofen tablets/caplets are being recalled due to complaints of odor related to CGMP deficiencies.
| Brand name | IBUPROFEN |
| Generic name | IBUPROFEN |
| Active ingredient(s) | IBUPROFEN |
| Distributed by / for | Marksans Pharma Inc. |
| NDC | 25000-114-30 |
| Full product label | Ibuprofen Tablets, USP 200 mg, 6 x 6500 Tablets bulk packed in double polybag shipper packs for further packaging, Rx only, Manufactured by: Marksans Pharma Ltd., Plot No. L-82, L-83, Verna Indl. Estate, Verna, Goa - 403 722, India, NDC 25000-114-30. |
| Recalling firm | Marksans Pharma Inc. |
| Distribution | Distributed to repackaging firms in NY who then distributed Nationwide in the USA. |
| Quantity | 205,088,000 tablets |
| Recall initiated | 2018-01-09 |
| Report date | 2018-01-31 |
| Recall completed | 2020-05-26 |
| Recall number | D-0237-2018 |
| Classification | Class II |
| FDA status | Terminated |
| Origin on file | Hauppauge NY United States |
Source: U.S. FDA enforcement database (openFDA). Look this up on the official FDA recalls site ↗